TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37486633
Drug: Mailed nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mailed nicotine patches
Study: 37486650
Drug: Intravenous Iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Iron supplementation
Study: 37486650
Drug: Oral Iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Iron supplementation
Study: 37486652
Drug: Cabergoline 1
Normalized name: cabergoline 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabergoline 1 mg once
Study: 37486775
Drug: Pitavastatin calcium
Normalized name: PITAVASTATIN CALCIUM
DrugBank: Pitavastatin (DB08860)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pitavastatin calcium 4 mg daily
Study: 37486952
Drug: Micronutrient-fortified balanced
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronutrient-fortified balanced energy-protein (BEP) supplementation and iron-folic acid (IFA) tablets
Study: 37487144
Drug: No adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: No adjuvant therapy in PORTEC-1 trial
Study: 37487169
Drug: Atezolizumab (1,200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atezolizumab (1,200 mg) once every 3 weeks
Study: 37487169
Drug: Atezolizumab (1,200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atezolizumab (1,200 mg) once every 3 weeks + Radiotherapy (RT)
Study: 37488191
Drug: Samuraciclib (360
Approvals — FDA: no, EMA: no, PMDA: no
Description: Samuraciclib (360 mg once daily)
Study: 37488191
Drug: Samuraciclib monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Samuraciclib monotherapy in TNBC
Study: 37488191
Drug: Samuraciclib in
Normalized name: Samuraciclib
DrugBank: Samuraciclib (DB16061)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Samuraciclib in combination with fulvestrant
Study: 37488287
Drug: Neoadjuvant PD-L1
Normalized name: dolutegravir
DrugBank: Dolutegravir (DB08930)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Neoadjuvant PD-L1 blockade with adebrelimab (two doses before surgery)
Study: 37488446
Drug: 2-OHOA (sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-OHOA (sodium 2-hydroxyoleate) at a maximum tolerated dose (MTD) of 12,000 mg/daily
Study: 37488580
Drug: Agalsidase beta
Normalized name: Agalsidase beta
DrugBank: Agalsidase beta (DB00103)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Agalsidase beta infusions <90 min
Study: 37488580
Drug: Agalsidase beta
Normalized name: Agalsidase beta
DrugBank: Agalsidase beta (DB00103)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Agalsidase beta infusions ≥90 min
Study: 37488580
Drug: Infusion rates
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Infusion rates
Study: 37488580
Drug: Anti-agalsidase beta
Normalized name: Agalsidase Beta
DrugBank: Agalsidase beta (DB00103)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Anti-agalsidase beta antibody-positive patients
Study: 37488588
Drug: MT-assisted ambulation
Normalized name: lipase
Approvals — FDA: no, EMA: no, PMDA: no
Description: MT-assisted ambulation up to three times daily, guided by the Johns Hopkins Mobility Goal Calculator, until hospital discharge or after 10 days.
Study: 37488627
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of two treatments (from the above options)
Study: 37488627
Drug: Single treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single treatment (from the above options)
Study: 37488734
Drug: holo beta-lactoglobulin
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: holo beta-lactoglobulin lozenge (holoBLG) 2x daily for 3 months
Study: 37488811
Drug: Risankizumab (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risankizumab (150 mg at weeks 0 and 4)
Study: 37489066
Drug: Durvalumab 1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durvalumab 1500 mg, tremelimumab 75 mg, cisplatin 80 mg/m²
Study: 37489066
Drug: Durvalumab with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durvalumab with tremelimumab and chemotherapy
Study: 37489819
Drug: FDA approved
Normalized name: glucose
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: FDA approved drugs matched to genomic targets
Study: 37489819
Drug: FDA approved
Normalized name: glucose
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: FDA approved drugs used outside their approved indications
Study: 37490017
Drug: Usual territorial
Normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual territorial rehabilitative treatments (UTRTs; control group)
Study: 37490085
Drug: Oral amoxicillin
Normalized name: amoxicillin Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral amoxicillin (90 mg/kg/d) and clavulanate (6.4 mg/kg/d) for 10 days (n=254)
Study: 37490085
Drug: Oral amoxicillin
Normalized name: amoxicillin Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral amoxicillin and clavulanate
Study: 37490337
Drug: Digital physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digital physical therapy (home exercise, education, CBT, device with movement digitalization, asynchronous monitoring)
Study: 37490337
Drug: Conventional physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional physical therapy (in-person exercises, manual therapy, education, CBT)
Study: 37490604
Drug: Flavored polyethylene
Normalized name: polyethylenes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flavored polyethylene glycol and sulfate solution (FPSS)
Study: 37490939
Drug: Nano-curcumin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nano-curcumin (40 mg)
Study: 37491084
Drug: Guided imagery
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guided imagery relaxation therapy in the form of a leaflet plus standard care
Study: 37491088
Drug: Daptomycin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daptomycin (10 mg/kg/d for 8 days)
Study: 37491309
Drug: TAK-228 (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-228 (4 mg) and TAK-117 (200 mg) orally each day for 3 days followed by 4 days off, weekly, until disease progression (PD)
Study: 37491309
Drug: Cisplatin (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (75 mg/m2) and nab paclitaxel therapy post PIKTOR
Study: 37491373
Drug: MOv18 IgE
Normalized name: IG
Approvals — FDA: no, EMA: no, PMDA: no
Description: MOv18 IgE antibody (dose escalation from 70 μg to 12 mg)
Study: 37491373
Drug: MOv18 IgE
Normalized name: IG
Approvals — FDA: no, EMA: no, PMDA: no
Description: MOv18 IgE antibody
Study: 37491568
Drug: OSA treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: OSA treatment
Study: 37491568
Drug: No OSA
Approvals — FDA: no, EMA: no, PMDA: no
Description: No OSA treatment or discontinued treatment
Study: 37491889
Drug: Lurbinectedin +
Normalized name: lurbinectedin
DrugBank: Lurbinectedin (DB12674)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lurbinectedin + ATR inhibitor berzosertib
Study: 37491938
Drug: zuranolone 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: zuranolone 50 mg/day
Study: 37492087
Drug: Qiangli Dingxuan
Normalized name: Dingxiang
DrugBank: Clove (DB10672)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qiangli Dingxuan tablet combined with amlodipine besylate
Study: 37492633
Drug: Oral paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral paclitaxel (oPAC) with encequidar (E) administered at 205 mg/m
Study: 37492635
Drug: Weekly reminders
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly reminders
Study: 37492920
Drug: Ligelizumab 120
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ligelizumab 120 mg
Study: 37492970
Drug: Endovascular therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular therapy with successful reperfusion (Thrombolysis in Cerebral Infarction score, 2b/3)
Study: 37492970
Drug: Endovascular therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular therapy with successful reperfusion at attempts 1
Study: 37492970
Drug: Endovascular therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular therapy with >2 recanalization attempts
Study: 37492976
Drug: 5-ASA co-treatment
Normalized name: CO
DrugBank: Carbon monoxide (DB11588)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-ASA co-treatment
Study: 37493020
Drug: Beta-blocker therapy
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blocker therapy for <12 months
Study: 37493020
Drug: Beta-blocker therapy
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blocker therapy for 12 to <24 months
Study: 37493020
Drug: Beta-blocker therapy
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blocker therapy for 24 to <36 months
Study: 37493020
Drug: Beta-blocker therapy
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blocker therapy for ≥36 months
Study: 37493020
Drug: Beta-blocker therapy
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blocker therapy for <36 months
Study: 37493229
Drug: Vaginal probiotic
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal probiotic suppository
Study: 37493229
Drug: Without vaginal
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Without vaginal probiotic suppository (Control)
Study: 37493269
Drug: RSV/6120/ΔNS2/1030s vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: RSV/6120/ΔNS2/1030s vaccine (105 PFU)
Study: 37493287
Drug: Sham injections
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham injections (sodium chloride 0.9%)
Study: 37493759
Drug: Combination Training
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination Training (COMB)
Study: 37493932
Drug: MedViewer (MV)
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MedViewer (MV) intervention providing real-time adherence feedback using IR-MALDESI mass spectrometry imaging of daily ART concentrations in hair.
Study: 37494014
Drug: Liraglutide, 3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide, 3.0 mg, once daily
Study: 37494101
Drug: Intravenous ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ketamine (1 mg/kg) as an adjunct to sedation protocol
Study: 37494101
Drug: Fentanyl (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (1.5 mcg/kg) and midazolam (2 mg)
Study: 37494942
Drug: Dolutegravir (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dolutegravir (50 mg), Emtricitabine (200 mg), Tenofovir Disoproxil Fumarate (300 mg)
Study: 37495197
Drug: Deep artificial
Normalized name: Deep Sea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deep artificial neural networks (DNNs) with data augmentation strategies
Study: 37495197
Drug: Modern DNNs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modern DNNs using augmentation
Study: 37495274
Drug: Subcutaneous Implantable
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous Implantable Cardioverter-Defibrillator (S-ICD)
Study: 37495276
Drug: Combination lipid-lowering
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination lipid-lowering therapy (rosuvastatin 10 mg plus ezetimibe 10 mg)
Study: 37496004
Drug: Afamelanotide 16
Normalized name: afamelanotide 16 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Afamelanotide 16 mg implants administered subcutaneously on Day 0, Day 1, and repeated on Day 7 and Day 8 if not well recovered.
Study: 37496004
Drug: Afamelanotide 16
Normalized name: afamelanotide 16 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Afamelanotide 16 mg implants administered subcutaneously.
Study: 37496298
Drug: parsaclisib 20
Normalized name: Parsaclisib
DrugBank: Parsaclisib (DB14867)
Approvals — FDA: no, EMA: no, PMDA: no
Description: parsaclisib 20 mg once daily for 8 weeks, followed by 20 mg once weekly thereafter, in combination with obinutuzumab and bendamustine
Study: 37496411
Drug: Intravenous injection
Normalized name: Meta Trace FDG, intravenous injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection of autologous bone marrow-derived mesenchymal stem cells (BM-MSCs)
Study: 37496612
Drug: Adintrevimab (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adintrevimab (300 mg intramuscular injection)
Study: 37497167
Drug: Parenteral treprostinil
Normalized name: Treprostinil
DrugBank: Treprostinil (DB00374)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Parenteral treprostinil initiated at 2 ng/kg/min intravenously or subcutaneously, with up-titration determined by clinicians
Study: 37497167
Drug: Rapid cross-titration
Normalized name: Red Cross Canker Sore
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rapid cross-titration in an inpatient setting (median: 2 days)
Study: 37497167
Drug: Gradual cross-titration
Normalized name: Red Cross Canker Sore
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gradual cross-titration in an outpatient setting (median: 5 days)
Study: 37497337
Drug: IRS-Low (IRS-L)
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: IRS-Low (IRS-L)
Study: 37497337
Drug: IRS-Ultra-Low (IRS-UL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IRS-Ultra-Low (IRS-UL) with chemotherapy
Study: 37497337
Drug: IRS-H with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: IRS-H with anti-PD-(L)1
Study: 37497354
Drug: Family-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family-based cognitive behavioral therapy (FCBT)
Study: 37497372
Drug: High-definition transcranial
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-definition transcranial direct current stimulation (HD-tDCS) over the primary motor cortex (M1), 10 daily sessions of 20 minutes each.
Study: 37497398
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose statins use (0.6% reported use, 212 individuals)
Study: 37497816
Drug: Compression with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compression with deferred endovenous treatment
Study: 37497888
Drug: SLN124 (1.0,
Approvals — FDA: no, EMA: no, PMDA: no
Description: SLN124 (1.0, 3.0, and 4.5 mg/kg)
Study: 37497921
Drug: Combination chemoimmunotherapy
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemoimmunotherapy and targeted treatment
Study: 37497921
Drug: Conventional therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapies (chemoimmunotherapy or targeted combinations)
Study: 37497921
Drug: CLL Treatment-Infection
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: CLL Treatment-Infection Model (machine learning-based algorithm)
Study: 37498105
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg of silkworm pupae extract (SWP) per day plus regular exercise (n=27)
Study: 37498596
Drug: Fosaprepitant weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosaprepitant weekly
Study: 37498661
Drug: Online Public
Approvals — FDA: no, EMA: no, PMDA: no
Description: Online Public Health Nurse-Delivered Group Cognitive Behavioral Therapy
Study: 37498821
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care plus up to 16 sessions of physical therapy
Study: 37499521
Drug: Binimetinib plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Binimetinib plus erlotinib (erlotinib 100 mg daily and binimetinib 15 mg BID × 5 days/week)
Study: 37499670
Drug: Camrelizumab 200
Normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Camrelizumab 200 mg intravenously every 2 weeks plus rivoceranib 250 mg orally once daily
Study: 37499679
Drug: Pfs230D1-EPA/Alhydrogel (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pfs230D1-EPA/Alhydrogel (40 μg)
Study: 37499679
Drug: Pfs25-EPA/Alhydrogel (47
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pfs25-EPA/Alhydrogel (47 μg)
Study: 37499679
Drug: Pfs25-EPA/Alhydrogel (47
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pfs25-EPA/Alhydrogel (47 μg) plus Pfs230D1-EPA/Alhydrogel (40 μg)
Study: 37500612
Drug: 3-weeks induction
Normalized name: etonogestrel
DrugBank: Etonogestrel (DB00294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3-weeks induction insulin therapy (glargine/lispro) followed by metformin maintenance with intermittent 2-week courses of insulin every 3-months for 2-years
Study: 37500612
Drug: 3-weeks induction
Normalized name: etonogestrel
DrugBank: Etonogestrel (DB00294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3-weeks induction insulin therapy (glargine/lispro) followed by metformin maintenance
Study: 37501016
Drug: gavo-cel (T
Approvals — FDA: no, EMA: no, PMDA: no
Description: gavo-cel (T cell receptor fusion construct) administered as a single agent (n=3) or after lymphodepletion (n=29)
Study: 37501016
Drug: gavo-cel (T
Approvals — FDA: no, EMA: no, PMDA: no
Description: gavo-cel (T cell receptor fusion construct)
Study: 37501180
Drug: Low-threshold HCV
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-threshold HCV treatment model at a syringe services program
Study: 37502440
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of UCA1, WRAP53, and serum α-fetoprotein (AFP)
Study: 37502622
Drug: AK0529 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: AK0529 2 mg/kg bid
Study: 37503157
Drug: Blood biomarker
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood biomarker panel (kidney injury molecule-1, N-terminal pro-B-type natriuretic peptide, osteopontin, and tissue inhibitor of metalloproteinase-1)
Study: 37503561
Drug: Anti-RBD IgG
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-RBD IgG concentrations ≥1000 BAU/mL
Study: 37503561
Drug: Anti-RBD IgG
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-RBD IgG concentrations ≥3000 BAU/mL
Study: 37503661
Drug: Encoberminogene rezmadenovec
Normalized name: Aglatimagene besadenovec
DrugBank: Aglatimagene besadenovec (DB15074)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Encoberminogene rezmadenovec (XC001) administered via epicardial delivery
Study: 37504371
Drug: Poor chemotherapy-induced
Approvals — FDA: no, EMA: no, PMDA: no
Description: Poor chemotherapy-induced tumor necrosis
Study: 37506264
Drug: Investigator-assigned standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigator-assigned standard therapy (IAT)
Study: 37506339
Drug: RD maintenance
Normalized name: OCTINOXATE 5 mg in 100 mL / AVOBENZONE 3 mg in 100 mL TOPICAL LOTION [Meaningful Beauty Cindy Crawford Maintenance 1 Daily Moisture SPF 8]
Approvals — FDA: no, EMA: no, PMDA: no
Description: RD maintenance therapy
Study: 37506557
Drug: T-cell vaccine
Normalized name: Virus Specific T-Cell
DrugBank: Virus Specific T-Cell (DB15735)
Approvals — FDA: no, EMA: no, PMDA: no
Description: T-cell vaccine combined with romidepsin (RMD)
Study: 37506557
Drug: Anti-CD33 antibody
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Anti-CD33 antibody
Study: 37506588
Drug: Tipapkinogene sovacivec
Normalized name: Tipapkinogene sovacivec
DrugBank: Tipapkinogene sovacivec (DB06239)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tipapkinogene sovacivec (TG4001) in combination with avelumab, administered subcutaneously at two dose levels weekly for 6 weeks, then every 2 weeks until 6 months, thereafter every 12 weeks.
Study: 37506599
Drug: Lacticaseibacillus paracasei
Normalized name: Lacticaseibacillus paracasei
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lacticaseibacillus paracasei 8700:2 (10 billion CFU) daily for 12 weeks
Study: 37506599
Drug: Lacticaseibacillus paracasei
Normalized name: Lacticaseibacillus paracasei
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lacticaseibacillus paracasei 8700:2 (10 billion CFU) daily for 12 weeks with ideal compliance
Study: 37507274
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of BNT162b2 mRNA COVID-19 vaccine
Study: 37507274
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (unvaccinated or vaccinated with other vaccines)
Study: 37507392
Drug: Low-dose ARVAC
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose ARVAC CG
Study: 37507392
Drug: High-dose ARVAC
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose ARVAC CG
Study: 37507425
Drug: Ruxolitinib (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ruxolitinib (10 mg twice daily for a median of 14 days)
Study: 37507543
Drug: Trastuzumab, lapatinib,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trastuzumab, lapatinib, or both in combination with chemotherapy
Study: 37507657
Drug: Galunisertib 150
Normalized name: SAPANISERTIB
DrugBank: Sapanisertib (DB11836)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galunisertib 150 mg twice daily (14 days on/14 days off) plus nivolumab 3 mg/kg (IV every 2 weeks)
Study: 37507667
Drug: Volunteer-led online
Normalized name: FILTER,SUCTION,INLINE #FHBF200S
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volunteer-led online group seated strength exercises using resistance bands, once weekly for 6 months
Study: 37507763
Drug: Nitrate-replete beetroot
Normalized name: Nitrate
DrugBank: Nitrate (DB14049)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrate-replete beetroot juice (400 mg nitrate/day)
Study: 37508992
Drug: Transcranial Direct
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcranial Direct Current Stimulation (tDCS) coupled with language therapy
Study: 37509349
Drug: Canady Helios
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canady Helios Cold Plasma (CHCP) treatment during surgical resection